Share on Facebook

Researchers at Belgian UCB SA have clinically demonstrated that an antibody targeting a normal cellular recycling process can remove autoantibodies from the blood of people with autoimmune diseases.

In a Phase I trial the team headed by Peter Kiessling demonstrated safety and tolerability of rozanolixizumab, a monoclonal antibody blocking FcRn – the protein domain that rescues IgG from being broken down. The findings could open up much needed therapeutic avenues where few options currently exist that remove self-reactive antibodies from the blood of people with autoimmune disorders without causing harmful side effects.